MarketCap
Facebook
X
TelegramAnnual report 2025
added 03-13-2026
Annovis Bio ROE Ratio 2011-2026 | ANVS
Annual ROE Ratio Annovis Bio
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -171.23 | -264.2 | 725.14 | -89.43 | -32.56 | -72.43 | 66.09 | 138.09 | 515.92 | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 725.14 | -264.2 | 90.6 |
Quarterly ROE Ratio Annovis Bio
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| -291.08 | -414.79 | -94.12 | 139.63 | -81.4 | -123.51 | -456.23 | -315.36 | -333.96 | -131.52 | -100.9 | -46.2 | -52.32 | -39.85 | -29.69 | -84.56 | -97.91 | -105.13 | -130.56 | -49.83 | -46.86 | -30.56 | 4.09 | 9.21 | 9.21 | 6.25 | 2.23 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 139.63 | -456.23 | -106.88 |
ROE Ratio of other stocks in the Biotechnology industry
| Issuer | ROE Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
Applied Genetic Technologies Corporation
AGTC
|
-62.37 | - | - | $ 26.5 M |  USA |
 |
MorphoSys AG
MOR
|
15.76 | - | 2.43 % | $ 254 M |  Germany |
 |
Allakos
ALLK
|
-110.0 | - | - | $ 28.6 M | USA |
 |
Advaxis
ADXS
|
196.88 | - | -9.65 % | $ 45.9 M | USA |
 |
Akouos
AKUS
|
-37.09 | - | 0.23 % | $ 488 M | USA |
 |
Compugen Ltd.
CGEN
|
34.4 | $ 2.54 | -6.92 % | $ 237 M |  Israel |
 |
AlloVir
ALVR
|
-55.11 | - | 4.14 % | $ 49.1 M | USA |
 |
I-Mab
IMAB
|
-85.31 | - | - | $ 866 M |  China |
 |
Aeglea BioTherapeutics
AGLE
|
-21.7 | - | - | $ 1.01 B | USA |
 |
Ampio Pharmaceuticals
AMPE
|
-256.9 | - | -11.43 % | $ 502 K | USA |
 |
Midatech Pharma plc
MTP
|
-330.29 | - | -18.52 % | $ 27.3 M |  Britain |
 |
Alexion Pharmaceuticals, Inc.
ALXN
|
5.18 | - | - | $ 40.3 B | USA |
 |
Aptorum Group Limited
APM
|
-5.9 | $ 0.88 | 0.34 % | $ 6.47 M | China |
 |
Biophytis SA
BPTS
|
-751.94 | - | -13.47 % | $ 169 M |  France |
 |
Genfit SA
GNFT
|
626.29 | - | 2.54 % | $ 160 B | France |
 |
ACADIA Pharmaceuticals
ACAD
|
30.9 | $ 22.08 | -2.6 % | $ 3.66 B | USA |
 |
Evogene Ltd.
EVGN
|
-41.09 | $ 0.76 | -4.13 % | $ 27.9 M | Israel |
 |
Fennec Pharmaceuticals
FENC
|
-27.46 | $ 6.31 | -5.82 % | $ 180 M | USA |
 |
EyeGate Pharmaceuticals, Inc.
EYEG
|
-115.61 | - | -1.52 % | $ 24.7 M | USA |
 |
Applied Molecular Transport
AMTI
|
-207.64 | - | - | $ 10.1 M | USA |
 |
AIkido Pharma
AIKI
|
-32.34 | - | 1.93 % | $ 17.4 M | USA |
 |
Galapagos NV
GLPG
|
-11.44 | $ 27.83 | -2.08 % | $ 2.69 B |  Belgium |
 |
Applied Therapeutics
APLT
|
698.49 | - | - | $ 8.42 M | USA |
 |
Aptinyx
APTX
|
-169.38 | - | -39.0 % | $ 4.57 M | USA |
 |
ImmuCell Corporation
ICCC
|
-3.84 | $ 8.38 | 0.36 % | $ 75.6 M | USA |
 |
Innoviva
INVA
|
23.12 | $ 23.02 | -2.83 % | $ 1.55 B | USA |
 |
Avenue Therapeutics
ATXI
|
-158.79 | - | -52.27 % | $ 4.45 M | USA |
 |
Институт стволовых клеток человека
ISKJ
|
17.55 | - | - | - |  Russia |
 |
Innate Pharma S.A.
IPHA
|
-41.02 | $ 1.49 | 6.43 % | $ 235 M | France |
 |
Inventiva S.A.
IVA
|
-30.23 | $ 4.89 | -2.5 % | $ 138 M | France |
 |
Jaguar Health
JAGX
|
286.68 | $ 0.23 | -6.35 % | $ 536 K | USA |
 |
Aeterna Zentaris
AEZS
|
-401.79 | - | 5.93 % | $ 314 M |  Canada |
 |
Ayala Pharmaceuticals
AYLA
|
3458.87 | - | - | $ 7.46 M | Israel |
 |
AgeX Therapeutics
AGE
|
51843.24 | - | -10.17 % | $ 12.2 K | USA |
 |
Aravive
ARAV
|
-716.17 | - | -13.39 % | $ 1.45 M | USA |
 |
Aridis Pharmaceuticals
ARDS
|
125.33 | - | 17.91 % | $ 11.1 M | USA |
 |
Atreca
BCEL
|
-123.92 | - | -11.76 % | $ 5.79 M | USA |
 |
BioNTech SE
BNTX
|
1.11 | $ 99.87 | -2.15 % | $ 27.2 B | Germany |
 |
Brainstorm Cell Therapeutics
BCLI
|
103.22 | - | -2.5 % | $ 5.88 M | USA |
 |
BioDelivery Sciences International
BDSI
|
45.18 | - | -4.8 % | $ 255 M | USA |
 |
Aquestive Therapeutics
AQST
|
248.9 | $ 4.03 | -1.59 % | $ 431 M | USA |
 |
Kamada Ltd.
KMDA
|
9.59 | $ 8.13 | -0.28 % | $ 260 M | Israel |
 |
Arcutis Biotherapeutics
ARQT
|
-8.52 | $ 22.18 | -4.79 % | $ 2.82 B | USA |
 |
Autolus Therapeutics plc
AUTL
|
-161.42 | $ 1.41 | -4.73 % | $ 375 M | Britain |
 |
Aptose Biosciences
APTO
|
93.75 | - | -45.71 % | $ 1.2 M | Canada |
 |
AstraZeneca PLC
AZN
|
20.44 | - | - | $ 96.9 B | Britain |
 |
AVROBIO
AVRO
|
12.83 | - | 1083.1 % | $ 745 M | USA |
 |
Can-Fite BioPharma Ltd.
CANF
|
-175.75 | $ 2.95 | 1.2 % | $ 4.86 M | Israel |
 |
BeiGene, Ltd.
BGNE
|
6.58 | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Madrigal Pharmaceuticals
MDGL
|
-47.83 | $ 513.45 | -0.63 % | $ 11.5 B | USA |